On July 7, 2020, the US Food and Drug Administration (FDA) made a historic decision concerning IQOS.
FDA authorized IQOS to be marketed in the US as a modified risk tobacco product (MRTP), with a reduced exposure claim. IQOS is the first and only tobacco heating system that has completed the US FDA Modified Risk Tobacco Product application process and received such status.
The US Food & Drug Administration (FDA) concluded that based on available scientific evidence:
For the past 10 years, we built a team of more than 400 scientists and R&D experts and have significantly invested towards one goal: creating an alternative to cigarettes for those adult smokers aged 21 and above, who want a better choice than continued smoking.
We are proud to celebrate this key milestone with you!
Important information: IQOS is not risk-free. It delivers nicotine, which is addictive. Only for people aged 21 and above.* Source: PMI 3-month reduced exposure studies conducted in Japan and the US in near real world conditions. These studies measured exposure to 15 harmful chemicals, and compared to the levels observed in smokers who switched to IQOS with levels measured in smokers who continued to smoke cigarettes.
**Source: FDA’s marketing order for the IQOS system dated July 7, 2020.